Squarepoint Portfolio holdings
Squarepoint runs funds that use computer models to trade many kinds of assets around the world. It began as nQuant, a trading unit set up inside Lehman Brothers in 2000 by its founders, Olivier Durantel and Gregoire Schneider. Barclays took over nQuant in 2008, and in December 2014 it was spun off as an independent firm and renamed Squarepoint. In 2022 Squarepoint formed STG, a separate trading group that shares much of its infrastructure but has its own investment staff, and in 2021 it partnered with Arini Capital, a European hedge fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Costco
COST
|
+$305M |
| 2 |
Procter & Gamble
PG
|
+$300M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$274M |
| 4 |
NVIDIA
NVDA
|
+$268M |
| 5 |
Lowe's Companies
LOW
|
+$253M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.23B |
| 2 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$536M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$470M |
| 4 |
ExxonMobil
XOM
|
+$370M |
| 5 |
Amazon
AMZN
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.61% |
| 2 | Technology | 13.44% |
| 3 | Consumer Discretionary | 5.63% |
| 4 | Financials | 5.29% |
| 5 | Healthcare | 5.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3351
CALL
Xenon Pharmaceuticals
XENE
$4.03B
| $498K | ﹤0.01% |
+13,400
| New | +$796K |
2026 Q3
0 quarters
|
|
3352
CALL
Aon
AON
$70.7B
| $498K | ﹤0.01% |
1,800
-5,400
| -75% | -$1.83M |
2024 Q4
7 quarters
|
|
3353
PUT
Microchip Technology
MCHP
$33.8B
| $498K | ﹤0.01% |
6,400
-114,900
| -95% | -$8.95M |
2024 Q1
10 quarters
|
|
3354
Logitech
LOGI
$14.3B
| $498K | ﹤0.01% |
4,927
-24,806
| -83% | -$2.52M |
2024 Q4
7 quarters
|
|
3355
Hyster-Yale Materials Handling
HY
$501M
| $497K | ﹤0.01% |
+15,792
| New | +$531K |
2026 Q3
0 quarters
|
|
3356
Cathay General Bancorp
CATY
$4.3B
| $496K | ﹤0.01% |
8,334
+2,630
| +46% | +$164K |
2026 Q2
1 quarter
|
|
3357
ALX Oncology
ALXO
$149M
| $495K | ﹤0.01% |
356,288
+309,419
| +660% | +$598K |
2026 Q2
1 quarter
|
|
3358
MiMedx Group
MDXG
$473M
| $495K | ﹤0.01% |
106,188
-465,742
| -81% | -$2.05M |
2023 Q2
13 quarters
|
|
3359
AerSale
ASLE
$245M
| $493K | ﹤0.01% |
94,063
-54,611
| -37% | -$319K |
2024 Q4
7 quarters
|
|
3360
RingCentral
RNG
$6.34B
| $493K | ﹤0.01% |
+6,594
| New | +$400K |
2026 Q3
0 quarters
|
|
|
ETRA
3361
Electra Therapeutics, Inc. Common stock
ETRA
$572M
| $492K | ﹤0.01% |
+43,768
| New | +$539K |
2026 Q3
0 quarters
|
|
3362
Twin Disc
TWIN
$358M
| $492K | ﹤0.01% |
18,787
-3,884
| -17% | -$92.2K |
2026 Q2
1 quarter
|
|
3363
Sanmina
SANM
$8.82B
| $491K | ﹤0.01% |
2,287
-68,703
| -97% | -$14M |
2024 Q3
8 quarters
|
|
3364
Ryman Hospitality Properties
RHP
$9.42B
| $491K | ﹤0.01% |
4,110
-2,562
| -38% | -$322K |
2025 Q4
3 quarters
|
|
3365
Manchester United
MANU
$3.94B
| $491K | ﹤0.01% |
23,446
+14,596
| +165% | +$321K |
2026 Q2
1 quarter
|
|
3366
Foghorn Therapeutics
FHTX
$123M
| $491K | ﹤0.01% |
137,435
+7,089
| +5% | +$37.3K |
2025 Q3
4 quarters
|
|
3367
PUT
Scotiabank
BNS
$113B
| $491K | ﹤0.01% |
+5,400
| New | +$486K |
2026 Q3
0 quarters
|
|
3368
RxSight
RXST
$226M
| $490K | ﹤0.01% |
100,047
+81,279
| +433% | +$477K |
2023 Q3
12 quarters
|
|
3369
ITT
ITT
$19.1B
| $490K | ﹤0.01% |
+2,429
| New | +$490K |
2026 Q3
0 quarters
|
|
|
PBLS
3370
Parabilis Medicines Inc
PBLS
$3.42B
| $490K | ﹤0.01% |
15,167
-33,317
| -69% | -$1.16M |
2026 Q2
1 quarter
|
|
3371
TIM SA
TIMB
$9.03B
| $489K | ﹤0.01% |
27,404
+1,181
| +5% | +$22.9K |
2026 Q1
2 quarters
|
|
3372
GH Research
GHRS
$1.27B
| $489K | ﹤0.01% |
20,811
+2,381
| +13% | +$66.1K |
2026 Q2
1 quarter
|
|
3373
PUT
Baker Hughes
BKR
$48.5B
| $489K | ﹤0.01% |
+8,900
| New | +$531K |
2026 Q3
0 quarters
|
|
3374
Corcept Therapeutics
CORT
$7.97B
| $489K | ﹤0.01% |
4,240
-324
| -7% | -$34.8K |
2026 Q2
1 quarter
|
|
3375
CALL
DELISTED
Roku
ROKU
| $487K | ﹤0.01% |
+3,200
| New | +$482K |
2026 Q3
0 quarters
|
|
Similar funds
Squarepoint's Q3 2026 Portfolio in Review
As of Q3 2026, Squarepoint held 5,201 positions worth $90.8B, up 0.33% from $90.5B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Squarepoint withdrew a net $4.18B in Q3 2026, closing 849 positions and reducing 1,820 holdings. Its most notable exit was Electronic Arts, an estimated $146M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 53% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Squarepoint opened a new position in AstraZeneca worth $188M.
- Squarepoint's largest Q3 2026 buy was AstraZeneca: 1,161,691 shares worth $188M.
- Squarepoint added most to Costco in Q3 2026, an estimated $305M increase.
- Squarepoint's biggest Q3 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $1.23B.
- Squarepoint fully exited Electronic Arts in Q3 2026, selling an estimated $146M.
- Squarepoint's ten largest holdings make up 22% of its $90.8B portfolio in Q3 2026.
- Squarepoint opened 873 new positions and closed 849 in Q3 2026.
- Squarepoint's portfolio value rose 0.33% quarter-over-quarter to $90.8B.
Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.